127 results
Page 4 of 7
8-K
EX-99.1
6sx5a 8bs
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
424B5
nq05o gztb1pdo1y0
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
nvte82hpmc6
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
4fnx6q 0qr
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
69aq2sj vumopnkef
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
lcku ez0hpa6hmpwl88t
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am
8-K
EX-99.1
vuqj37 u4diu
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
3vpis
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-10.1
vifoad im2
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
3b8gcc9y0cul
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
h95an2z4pndehkw h4g
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
3h0z9 pkj
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am